Susquehanna Fundamental Investments LLC bought a new stake in McKesson Co. (NYSE:MCK – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,953 shares of the company’s stock, valued at approximately $6,397,000.
Several other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in McKesson by 1.1% in the 1st quarter. JPMorgan Chase & Co. now owns 4,362,837 shares of the company’s stock worth $2,342,190,000 after purchasing an additional 46,659 shares during the period. Putnam Investments LLC raised its holdings in shares of McKesson by 3.2% in the fourth quarter. Putnam Investments LLC now owns 1,997,963 shares of the company’s stock worth $925,017,000 after buying an additional 62,242 shares during the period. Legal & General Group Plc raised its holdings in shares of McKesson by 2.9% in the second quarter. Legal & General Group Plc now owns 1,297,620 shares of the company’s stock worth $757,862,000 after buying an additional 36,583 shares during the period. Swedbank AB bought a new stake in shares of McKesson during the 1st quarter worth approximately $669,326,000. Finally, Boston Partners boosted its holdings in McKesson by 4.1% during the 1st quarter. Boston Partners now owns 1,183,829 shares of the company’s stock valued at $635,763,000 after acquiring an additional 47,140 shares during the period. Institutional investors own 85.07% of the company’s stock.
Insider Activity
In related news, CEO Brian S. Tyler sold 3,753 shares of the business’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $626.03, for a total transaction of $2,349,490.59. Following the transaction, the chief executive officer now directly owns 82,339 shares in the company, valued at approximately $51,546,684.17. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders sold 11,259 shares of company stock worth $6,635,492. Insiders own 0.11% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on MCK
McKesson Price Performance
Shares of NYSE MCK opened at $488.25 on Friday. McKesson Co. has a 1-year low of $431.35 and a 1-year high of $637.51. The business has a fifty day moving average price of $550.84 and a 200 day moving average price of $555.57. The stock has a market capitalization of $63.44 billion, a P/E ratio of 21.82, a price-to-earnings-growth ratio of 1.18 and a beta of 0.44.
McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, beating the consensus estimate of $7.21 by $0.67. McKesson had a net margin of 0.94% and a negative return on equity of 242.57%. The business had revenue of $79.28 billion during the quarter, compared to analyst estimates of $82.53 billion. During the same period in the prior year, the firm posted $7.27 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, equities research analysts anticipate that McKesson Co. will post 32.07 earnings per share for the current fiscal year.
McKesson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Monday, September 2nd will be issued a $0.71 dividend. This is a positive change from McKesson’s previous quarterly dividend of $0.62. This represents a $2.84 annualized dividend and a yield of 0.58%. The ex-dividend date is Friday, August 30th. McKesson’s payout ratio is currently 12.69%.
McKesson Company Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Featured Articles
- Five stocks we like better than McKesson
- CD Calculator: Certificate of Deposit Calculator
- CarMax’s Impressive Rally: What Investors Should Watch Next
- About the Markup Calculator
- MarketBeat Week in Review – 9/23 – 9/27
- Energy and Oil Stocks Explained
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.